![]() |
CiteULike | ![]() |
zimbo1's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidinesby: Roger J. Gillespie, Samantha J. Bamford, Ruth Botting, Mike Comer, Sarah Denny, Suneel Gaur, Michael Griffin, Allan M. Jordan, Anthony R. Knight, Joanne Lerpiniere, Stefania Leonardi, Sean Lightowler, Steven Mcateer, Angela Merrett, Anil Misra, Antony Padfield, Mark Reece, Mona Saadi, Daniel L. Selwood, Gemma C. Stratton, Dominic Surry, Richard Todd, Xin Tong, Vicki Ruston, Rebecca Upton, Scott M. Weiss
|
Reviews
[Write a review of this article]
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
Abstractdoi: 10.1021/jm800961g Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms associated with Parkinson’s disease. This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine. We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivatives that display functional antagonism of the A2A receptor. Optimization of these compounds has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivatives. These efforts have led to the discovery of 60 (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson’s disease. Furthermore, this derivative has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies. This compound is presently undergoing further clinical evaluation in collaboration with Biogen Idec.
BibTeX record
RIS record